Please find below some recent news of relevance for the life sciences sector as well as press releases and publications published by us.
We regularly publish interesting news on legal life sciences matters and beyond, such as seminars, publications and other news from our law firm, via our LinkedIn account NOVACOS Law.
Follow us on LinkedIn and receive regular updates
You will also find selected news items below:
We are proud that NOVACOS has already been included in the JUVE-Ranking of the best German law firms in the area of healthcare and life sciences (view ranking).
The new JUVE publication (2016/2017) ranking commercial law firms already recommends NOVACOS as a spin-off focused solely on life sciences …
Our Partner Dr. Christian Stallberg will talk on 8 June 2017 in Baiersbronn as part of an expert panel about the latest court decisions and legislation on pharma law. The main topics are, inter alia, pricing and reimbursement legal issues, unfair competition and advertising law for drugs as well as …
Our partner Dr. Christian Stallberg will chair a round table on health policy with members of the German Parliament on 21 June 2017 in Berlin. The participants will discuss the past legislation on public health and talk about lessons for the forthcoming legislative period. One main topic will be the …
Our partner Dr. Christian Stallberg will talk about the legal framework and principles of the reimbursement for medical devices under the German public health insurance system on 27 June 2017 in Hamburg. The talk will cover reimbursement issues in both homecare as well hospitals. In addition, he will discuss issues …
Our partner Dr. Christian Stallberg will talk about the legal framework and core principles of the German public health insurance system on 30 August 2017 in Frankfurt. The objektive is to provide participants with an overview of in-patient and out-patient regulation on reimbursement of pharmaceuticals and medical devices. For further …
The European Court of Justice (ECJ) decided today that the German law requesting one fixed ex-factory and retail price for a prescription (Rx) medicine infringes Art. 34 TFEU and is not justified if it prohibits foreign internet pharmacies from selling at a lower price in Germany. Hence, price competition within …